C3, Equipmed sign distribution agreements
Monday, 27 October, 2003
Perth-based tissue engineering company Clinical Cell Culture (C3, ASX: CCE) has signed distribution agreements with Equipmed to distribute C3's CellSpray and ReCell products in Australia, excluding Western Australia, and New Zealand.
The ReCell agreement will be activated once TGA approval has been obtained for general marketing of the product. The agreements have three year terms and including marketing and support activities.
C3 CEO Troels Jordansen said the company was pleased to have an agreement with Equipmed, which has experience in the plastic and cosmetic surgery market and distributes tissue engineering products from international company Isolagen.
C3 is planning to expand its business internationally next year, with a European production facility in the works and sales of ReCell in 15 companies around the world expected.
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
